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Abstract
Neurofibromatosis type 1, including the highly aggressive malignant peripheral nerve sheath 
tumors (MPNSTs), is featured by the loss of functional neurofibromin 1 (NF1) protein resulting 
from genetic alterations. A major function of NF1 is suppressing Ras activities, which is conveyed 
by an intrinsic GTPase-activating protein-related domain (GRD). In this study, we explored the 
feasibility of restoring Ras GTPase via exogenous expression of various GRD constructs via gene 
delivery using a panel of adeno-associated virus (AAV) vectors in MPNST and human Schwann 
cells (HSC). We demonstrated that several AAV serotypes achieved favorable transduction 
efficacies in those cells and a membrane-targeting GRD fused with an H-Ras C-terminal motif 
(C10) dramatically inhibited the Ras pathway and MPNST cells in a NF1-specific manner. Our 
results opened up a venue of gene replacement therapy in NF1-related tumors.
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Introduction
The RASopathy neurofibromatosis 1 is an autosomal dominant hereditary cancer syndrome 
that affects ~1:3,000 individuals [1, 2]. Neurofibromatosis 1 is caused by mutations of the 
neurofibromin 1 (NF1) tumor suppressor gene at 17q11.2, which encodes the GTPase-
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activating protein (GAP) NF1 that catalyzes the inactivation of Ras by accelerating GTP 
hydrolysis to GDP [3, 4]. In affected individuals, truncation or loss of NF1 results in 
constitutively activated Ras with subsequent activation of the RAF–MEK–ERK cascade. 
This Ras hyperactivation supports the frequent development of multiple benign tumors, as in 
plexiform and cutaneous neurofibromas, and less frequently malignancies.
A hallmark of neurofibromatosis 1 is the presence of benign plexiform neurofibromas 
(pNFs) in which biallelic-inactivating mutations in the NF1 gene in Schwann cells occur and 
provides a selective growth advantage to a normal Schwann cell [2, 5]. About 8–13% of 
pNFs undergo cancerous transformation into a malignant peripheral nerve sheath tumor 
(MPNST) through a course of molecular evolution during which accumulated genetic 
mutations in CDKN2A/B, TP53 and other genes as well as epigenetic alternations affect the 
regulation of multiple cellular processes [2, 6]. This transformation evolves over many years 
and typically affects young adults with neurofibromatosis 1 in their 20s-30s, with MPNSTs 
representing the leading cause of mortality in this patient population [7, 8].
The treatment of MPNSTs has unfortunately been extremely challenging. To date, surgery is 
the only treatment modality proven to have survival benefit for MPNSTs. However, even 
when maximal surgery with wide surgical margins is feasible, these tumors are almost never 
curable [8, 9] and about 50% of patients will succumb to this condition within 5 years after 
initial diagnosis, reflecting the urgent need for new and more effective therapeutics for this 
cancer.
One very promising but largely unexplored concept in the treatment of NF1-related 
MPNSTs is gene therapy. Over the past years, delivery vectors based on recombinant adeno-
associated virus (AAVs) have shown great promise and achieved clinically meaningful long-
term gene expression leading to regulatory approval for some conditions such as hemophilia, 
cystic fibrosis and spinal muscular atrophy (SMA) [10–12].
The recombinant AAV is a non-pathogenic, non-replicating parvovirus because rep and cap 
genes are cloned in a trans-plasmid without inverted terminal repeats (ITR). To date more 
than 100 natural occurring human and non-human primate AAV serotypes have been 
identified [13]. Unlike lentivirus, it does not cause any human disease and has a reduced 
carcinogenicity because it only rarely integrates into the genome of the host cell. It is 
capable of infecting both dividing and quiescent cells with a low host immune recognition. 
Notably, advancements in our understanding of AAV capsid structure have facilitated the 
rational design of AAV capsids to restrict or redirect viral tropism and transduction, and 
considerable progress in both AAV capsid library development and screening methodology 
has enabled directed evolution of AAV capsids, which will ultimately ensure that transgene 
expression is reproducible, robust, and occurs over an extended period [13–15].
Gene delivery vectors based on AAVs have a packaging capacity of up to ~4.7 kb at near 
wild-type titers and infectivity; beyond this size, packaging efficiency markedly decreases, 
and genomes with 5ʹ truncations become encapsidated [14]. Although NF1’s cDNA of 8.5 
kb is too large for AAV vectors, the NF1-GAP-related domain (NF1-GRD), a ~1kB small 
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subunit of the gene, is presumably solely responsible for deactivating Ras activity [16, 17] 
and, thus making neurofibromatosis 1 uniquely suitable for AAV based gene delivery.
In this study, we have screened a panel of available AAV vectors in MPNST and primary 
Schwann cells to profile transduction efficacies of different serotypes in order to reveal 
potential templates for future engineering of the AAV capsid. We also tested the inhibition of 
the Ras pathway in NF1-related MPNST cells using GRD optimized for membrane-
targeting.
Materials and Methods
Tissue culture and cell lines
Human NF1-associated MPNST cell lines NF90.8 and ST88–14 were provided by Dr. 
Michael Tainsky (Wayne University, Detroit, MI) and sNF96.2 was purchased from ATCC 
(Manassas, VA). NF90–8, ST88–14, sNF96.2 and STS26T MPNST cell lines were cultured 
in DMEM (ATCC) media supplemented with 10% FBS (Sigma) and penicillin/streptomycin 
(Gibco). These cell lines were not authenticated. Human Schwann cells isolated from spinal 
nerve were purchased from ScienCell Research Laboratories and maintained in DMEM 
media supplemented with 3% FBS, penicillin/streptomycin, and heregulin-1 (PeproTech) 20 
ng/ml and 2 μM forskolin (Sigma). All cells were tested and found free of mycoplasma 
contamination.
Reagents and antibodies
The rabbit anti-phospho-Erk1/2 (p44/42 MAPK) (Thr202/Tyr204) antibody (#9101, Lot 23) 
and anti-Erk1/2 (p44/42 MAPK) antibody (#9102, Lot 27) were purchased from Cell 
Signaling Technologies. Rabbit anti-NF1 antibody (A300–140A, Lot 3) was purchased from 
Bethyl laboratories, mouse anit-HA antibody (26183, Lot RJ241582) was purchased from 
Invitrogen and anti-βActin (C-11, SC-1615HRP, Lot G3015) HRP antibody was purchased 
from Santa Cruz Biotech. Active Ras Detection Kit (#8821, antibody Lot 7) was purchased 
from Cell Signaling Technology. NucBlue Live Ready Probes was purchased from 
Invitrogen.
NF1-GRD constructs
Human NF1 transcript variant 2 (NM_000267.3) of 2818 amino acids (AA) was used as the 
template sequence. The GRD sequence of NF1 (AA 1172–1538) as described before [18], 
was cloned with a C-terminal 2xHA tag into the lentivirus pFUGW and pscAAV-MCS (Cell 
Biolabs, VPK-430) vectors. To create a membrane-targeting GRD construct (GRD-C10), a 
2xHA sequence was fused to the N-terminus of GRD and a sequence encoding the H-Ras C-
terminal 10 AA (GCMSCKCVLS) containing the CAAX motif was attached in frame to the 
GRD C-terminus.
Lentiviral production and transduction
EGFP or GRD-2HA was cloned in pFUGW vector and the plasmid was transfected along 
with CMVΔR8.91 and pMD.G in 293T cells by Lipofectamine 2000 (Invitrogen). Virus was 
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harvested after 48 hours and infected MPNST cells by incubating with 8 μg/ml polybrene 
(Sigma).
AAV plasmids
pscAAV was purchased from Cell Biolabs, Inc. We obtained 13 hybrid pAAV-Rep-Cap 
(pAAV-RC) vectors, which encode the rep of AAV2 and variable cap genes of different 
serotypes. Among them, pAAV2-RC was purchased from Stratagene, pAAV-RC3B, pAAV-
RC4, pAAV-RC6 and pAAV-DJ were purchased from Cell Biolabs, and pAAV2/1, pAAV2/5 
JC, pAAV2/7, pAAV2/8, pAAV9n, pAAV2/rh10, pAAV2/hu11 and pAAV2/rh32.33 were 
obtained from Penn Vector Core of the University of Pennsylvania. For AAV packaging, the 
pHelper plasmid (Stratagene) and AAVpro-293T cells (Clontech) were used.
AAV production and purification
pAAV-Rep-Cap, pscAAV and pHelper plasmids in equal amount were transfected in 
AAVpro-293T cells by Lipofectamine 2000 in DMEM media supplemented with 10% FBS. 
After 3 days, cells were harvested and AAVs were purified by AAVpro Purification Kit of 
Clontech following the manufacturer’s instruction. Viral titers were determined by AAVpro 
Titration Kit from Clontech using real-time PCR.
AAV transduction and fluorescence microscopy
In a flat bottomed 96 well plate, 5000 of HSC or MPNST cells were plated in each well. 
AAV vectors with EGFP were incubated at MOI 1000 or MOI 5000 in 60 μl in the regular 
growth media for 5 days. Medium was then changed to FreeStyle 293 Expression medium 
(Gibco) without Phenol Red added with NucBlue Live Cell Stain ReadyProbes (Invitrogen) 
that stained the nuclei to blue fluorescence. The cells have reached complete confluence and 
the green fluorescence signals were quantified on a PerkinElmer VICTOR3 1420 Multilabel 
Counter with a green fluorescence (485/535 nm) filter set. EGFP signals were subsequently 
examined on an immunofluorescence microscope. Three biological samples were measured 
in each experiment.
Immunofluorescence Staining
The staining followed the procedure described before [19]. Cells were grown in medium on 
chamber slides (Nunc) and treated as indicated. Cells were washed with PBS and fixed for 
10 min with 4% paraformaldehyde solution and permeated with methanol for 2 min with 3 
washes in PBS in between and after. The slides were first blocked by 10% goat serum in 
PBS for 1 h at room temperature and incubated with the first antibody and subsequently with 
AlexaFluor 488 (Green) secondary antibody (Invitrogen) in 10% goat serum in PBS at room 
temperature. They were then washed 3 times in PBS in between and after. After staining, the 
slides were covered with mounting medium containing DAPI (Vector Laboratories) and 
examined on a fluorescence microscope.
Western Blots
Cells were lysed in buffer as described previously [20] [19]. Briefly, cells were suspended in 
lysis buffer (10 mM Tris-HCl pH 7.5, 130 mM NaCl, 5 mM EDTA, 0.5% Triton X-100, 20 
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mM sodium phosphate pH 7.5, 10 mM sodium pyrophosphate pH 7.0, 50 mM NaF, 1 mM 
sodium orthovanadate,1 mM phenylmethylsulfonyl fluoride, and protease inhibitor cocktail 
[Roche]) and kept on ice for 10 min before being centrifuged. Cell lysates were heated for 5 
min with LDS Sample Buffer (Invitrogen) supplemented with 100 mM DTT before loading 
onto a 4–12% NuPAGE Bis-Tris Gel (Invitrogen). After transfer to a PVDF membrane (Bio-
Rad), immunostaining was performed according to standard procedure. Signals were 
visualized by the Super Signal chemiluminescent system (Pierce, Rockford, IL). 
Experiments were repeated twice.
Assay of active Ras
Ras activities in MPNST cells were examined by the Active Ras Detection Kit (#8821, Cell 
Signaling Technology) following manufacturer’s instuction. Briefly, the cell lysates were 
incubated with GST-Raf1-RBD and glutathione resin. After wash and centrifugation, the 
bound fractions of Ras were dissociate and denatured in SDS sample buffer with DTT, and 
examined by anti-Ras western blotting. Pre-incubating the lysates with 0.1 mM GTPγS or 1 
mM GDP before binding with GST-Raf1-RBD created positive or negative control, 
respectively. Experiments were repeated twice.
Cell Growth Assay
The viable cells were measured with Cell Counting Kit-8 (Dojindo Laboratories, Japan) 
containing WST-8 tetrazolium salt at 450 nm on a PerkinElmer VICTOR3 plate reader. 
Three biological samples were measured in each experiment.
Flow Cytometry
Analysis of EGFP-positive cells—NF90–8 cells in6-well plates were incubated with 
AAV-DJ-EGFP at MOI 1000 or 5000 for 36 hrs. Cells were harvested by trypsinization, 
counterstained by incubating with 28 mM DAPI for 5 min in the flow buffer (PBS with 4% 
FBS and 1 mM EDTA), washed and analyzed by a BD FACSAria Fusion at the FITC 
channel. Control was untransfected cells. Three independent samples were measured and 
data were analyzed by two-tailed t-test.
Staining of GRD-2HA and GRD-C10–2HA transfected by AAV-DJ—NF90–8 cells 
in 6-well plates were incubated with AAV-DJ control, AAV-DJ-GRD-2HA or AAV-DJ-
GRD-C10–2HA at MOI 5000 for 36 hrs. Cells were trypsinized, fixated by the IC fixation 
buffer (Invitrogen, #00–8222), permeabilized by the permeabilization buffer (Invitrogen, 
#00–8333) and incubated with anti-HA antibody conjugated with AlexaFluor 647 (R&D 
Systems, #IC6875R) at 5 μl/ 106 cells in 100 μl permeabilization buffer for 45 min at RT. 
Cells were then washed twice in 2 ml permeabilization buffer, resuspended in 0.5 ml flow 
buffer and analyzed by a BD FACSAria Fusion. Data were obtained from three independent 
samples and analyzed by two-tailed t-test.
Propidium Iodide (PI) Staining—Cells were plated in 6-well plates and transduced with 
indicated AAVs. After 2 days, cells were trypsinized, washed, pelleted and fixated with 70% 
ethanol at the final concentration on ice for 15 min. Cells were then centrifuged and 
incubated with 500 μl PI-solution in PBS (50 μg/ml PI, 0.1 mg/ml RNase A, 0.05% Tritin 
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X-100) at 37°C for 40 min. Subsequently, cells were washed and resuspended in PBS and 
analyzed with a BD FACSymphony A3 flow cytometer using the PE-Gr-A channel. Results 
were analyzed with FlowJo version 10.
Statistical Analysis
The results are presented as a mean value plus or minus the standard deviation. Data were 
analyzed by GraphPad Prism 5.0. The p-values were determined by a Mantel-Cox test. A p-
value under 0.05 was accepted as statistically significant. Sample sizes were chosen to 
achieve statistical significance.
Results
1. NF1-GRD suppressed the RAS activity and the growth of MPNST cells
Expressing the GRD domain of NF1 could restore normal growth in NF1−/− NF1-deficient 
hematopoietic cells, fibroblasts and neural stem cells [16, 17]. Likewise, the effects of the 
GRD have also been demonstrated in MPNST cells [21, 22].
In this study, we first subcloned the GRD domain of human NF1 into the pFUGW lentivirus 
(LV) vector with a C-terminal double HA tag (2HA) for sensitive in vitro and in vivo 
detection. Human MPNST cells NF90.8, sNF96.2 and ST88–14 were derived from patients 
with neurofibromatosis 1 and lacked the wildtype (WT) NF1 gene, whereas both STS26T 
cells derived from a sporadic MPNST and primary human Schwann cells isolated from 
spinal nerve expressed functional NF1 [23]. Figure 1A confirmed the expression status of 
NF1 protein in these cells. As shown in Figure 1B, the GRD-2HA construct was able to 
significantly reduce the aberrant Ras activity in ST88–14 and NF90.8 cells in the GST-Raf1-
RBD pulldown assay suggesting that the GAP domain of NF1 compliments the inability of 
these cells to inactivate RAS. The replacement of the NF1-GRD via lentiviral transduction 
significantly suppressed the growth of NF90.8, sNF96.2 and ST88–14 cells, compared to the 
EGFP construct as control (Fig. 1C).
Next, we compared the transduction efficacy of a panel of commercially available AAV 
vectors in MPNST and primary human Schwann cells by expressing EGFP and quantifying 
the green fluorescent signals. We used 13 hybrid pAAV-Rep-Cap (pAAV-RC) vectors, which 
encode the rep of AAV2 and variable cap genes of different serotypes, including AAV1 
(pAAV2/1), AAV2 (pAAV2-RC), AAV3B (pAAV-RC3B), AAV4 (pAAV-RC4), AAV5 
(pAAV2/5 JC), AAV6 (pAAV-RC6), AAV7 (pAAV2/7), AAV8 (pAAV2/8), AAV9 
(pAAV9n), AAV10 (pAAV2/rh10), AAV11 (pAAV2/hu11) and AAV32/33 (pAAV2/rh32.33) 
as well as the synthetic AAV-DJ (pAAV-DJ) [24–27] [28], along with the pHelper and self-
complimentary pscAAV (pscAAV-MCS) expression vector to enhance the transduction [29]. 
The pscAAV vector uses the CMV promoter to express the transgene. After production, 
purification and quantification of AAVs, 5000 ST88–14, NF90–8 or sNF96.2 cells were 
plated in 96-well plates and incubated with indicated AAVs at MOI 1000 or 5000. Cells 
were allowed to grow five days to reach complete confluence as examined optically by 
microscope. Green fluorescent signals in each well were quantified by a plate reader, which 
reflected the expression levels of EGFP in the transduced cells. At an MOI of 5000, AAV2, 
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3B and DJ demonstrated superior transduction of EGFP in ST88–14 cells, while in NF90–8 
cells, AAV1, 2, 3B, 6 and DJ showed significant transduction in contrast to other AAVs (Fig. 
2A and C). Cells incubated at MOI of 1000 followed a similar trend. The results were 
consistent with the observation of the fluorescence microscopy, where all the cells were 
photographed and either selectively shown in Fig. 2B and D or not shown. In sNF96.2 cells, 
AAV1, 2, 3B and DJ again stood out both at MOI 5000 and 1000 (Fig. 3A and B). Using 
flow cytometry, we measured in average 98.7% and 99.1% NF90–8 cells were positive of 
EGFP at MOI 1000 and 5000 of AAV-DJ-EGFP, respectively, with higher expression levels 
observed at MOI 5000 (Supplementary Fig. 1).
It has been established that neurofibromastosis 1 and MPNST are originated from Schwann 
cells [2, 30]. A gene replacement therapy restoring NF1 functions could also benefit the 
patients before the malignant transformation in NF1 haploid cells, most importantly the 
Schwann cells. We transduced primary human Schwann cells (HSC) that are positive of 
S-100 staining (Fig. 3C) with 13 AAV vectors encoding EGFP and found AAV 1, 2, 6 and 
DJ delivered EGFP most efficaciously (Fig. 3D and E).
Next, we tested GRD constructs with AAV-DJ, one of the relatively efficacious AAV vectors 
consistently among MPNST and HSC. Because RAS proteins are attached to the cellular 
membrane through prenylation and palmitoylation of cysteine residues including a CAAX 
motif located in the C-terminal hypervariable region (HVR) that is sufficient to confer 
targeting to plasma membrane [31–33], we created a GRD construct fused with the 10 
amino acids of H-Ras C-terminus (C10) containing the palmitoylation sites and CAAX 
motif, with a double HA tag at the N-terminus. When transduced by AAV-DJ in NF90–8 
cells, GRD-C10 drastically outperformed GRD in suppressing the phosphorylation of Erk1/2 
(pErk1/2) where a reduced pERK1/2 signal with GRD and no pErk1/2 signal with GRD-C10 
was detected, while GRD-C10 showed a relatively low expression level in those cells (Fig. 
4A). Using intracellular anti-HA staining and flow cytometry, we found that in average 
13.2% and 9.8% NF90–8 cells were stained positive 36 hrs after transfected by AAV-DJ-
GRD and AAV-DJ-GRD-C10 at MOI 5000, respectively (Supplementary Fig. 2). 
Immunofluorescence staining of HA demonstrated the membrane-targeting of GRD-C10 
(Fig. 4B). GRD-C10 markedly outperformed GRD in suppressing the growth of ST88–14, 
NF90–8 and sNF96.2 cells (Fig. 4C–E). Cell cycle analysis of NF90–8 and ST88–14 cells 
indicated significantly less cells in G2/M phase and more cells in Sub-G0 48 hours after 
transduced with AAV-DJ-GRD-C10 compared to those with the control AAV-DJ (Fig. 4F 
and G, Suppl. Fig. 3). In contrast, despite being transducible with AAV-DJ (Fig. 5A and B), 
STS26C cells, a spontaneous MPNST cell line with intact NF1 (Fig. 1A), were not affected 
by GRD and GRD-C10 (Fig. 5C). Similarly, HSCs was not suppressed by GRD at all and 
also not by GRD-C10 at a significant level (Fig. 5D).
Discussion
The major challenge facing therapies using AAVs is the poor efficacy in delivery, to which 
many efforts have been directed in modifying and optimizing the AAV cap gene [34]. For 
example, aiming to improve targeting and reduce anti-AAV immunity, recombinant AAV-DJ 
was created via DNA shuffling and immuno-selection from cap genes of 8 natural serotypes 
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and markedly outperformed all the parental AAV vectors in vitro [28]. Further engineering 
of AAV-DJ resulted in drastically improved delivery in various mice tissues [28, 35]. In this 
study, we analyzed the transduction efficacies of recombinant vectors distinct from each 
other only on capsids of 12 natural serotypes of human and monkey origins and the synthetic 
AAV-DJ, in various MPNST cells and HSC. The consensual AAV1, 2, 3B and DJ as well as 
AAV6 that transduced HSC and NF90–8 particularly efficiently, can be used in testing in 
vivo and included as templates in future engineering efforts to improve targeting in MPNST 
and HSC in vitro and further in vivo.
Although AAV has not been tested with MPNST cells in previous publications before, 
Hoyng et al. have reported transduction of primary human and rat Schwann cells with AAV 
serotypes 1–9 carrying GFP in culture and in nerve segments [36]. In that study, AAV2 and 
AAV6 outperformed other vectors in cultured HSC, which is largely consistent with our 
finding in Fig. 3D.
NF1 is a large protein with various domains of complex functionalities, including cysteine 
serine-rich domain (CSRD), tubulin-binding domain (TBD), GRD, Sec14, PH-like domain 
and FAK-binding region [37]. A GRD version of 333 amino acids (AA) (NF1–333, AA 
1198–1530) has been extensively investigated, which revealed a central minimal GAP 
domain of 230 AA (AA 1248–1477) and flanking extra regions that also appeared to 
mediate important GAP-related functions and interactions [37–39]. In physiological 
conditions, NF1 protein is recruited to the plasma membrane by interacting with Spred1, 
which has been mapped between Spred1 EVH1 domain and GRD’s N- (AA 1202–1217) and 
C-terminal (AA 1511–1530) extra regions [40–42]. In this study, we used a slightly larger 
GRD sequence (AA 1172–1538) in our construct with a double HA tag [18]. This construct 
presented a diffused subcellular distribution in MPNST cells upon viral transduction. The C-
terminal HVRs of Ras proteins with the CAAX motif contain cysteine residues subject to 
prenylation and palmitoylation that confer the targeting to the plasma membrane. For 
example, the C-terminal 11 AA, 10 AA, and 20 AA of respective N-Ras, H-Ras and K-
Ras4B have been shown to re-target an exogenously expressed protein to the plasma 
membrane [31, 33]. In order to improve the targeting on membrane-associated Ras proteins, 
GRD was fused with an H-Ras C10 sequence containing cysteine 181 and 184 as well as the 
CAAX motif. This GRD-C10 construct drastically enhanced GRD’s potency in suppressing 
pErk1/2 and the growth of NF1-related MPNST cells, with remarkable specificity as shown 
in contrast to NF1-unrelated MPNST cells and HSC. Thus, given its potency and specificity, 
GRD-C10 would be well suited in a gene replacement therapy in MPNST and NF1-haploid 
individuals in future development. In such a therapy, a noticeable efficacy would entail 
almost all of the MPNST cells or the majority of the NF1-haploid Schwann cells to receive 
the GRD-C10 transgene, since the non-transduced populations exhibit a clear growth 
advantage. With the current available tools for in vivo gene delivery, this would be only 
feasible with a drastically improved AAV vector for MPNST or Schwann cells, which could 
possibly be achieved through protein engineering of the AAV capsids. We further reason that 
a gene replacement therapy may have a good chance of success as a preventative measure 
before the malignant transformation to MPNST occurs by repeatedly targeting NF1-haploid 
Schwann cells that grow less aggressively than MPNST cells. Alternatively, approaches to 
upregulate the expression of NF1 on the intact allele in NF1-haploid cells can also be 
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considered, for example via techniques with specific recognition such as CRISPR-dCas9-
VPR, where the nuclease-null Cas9 is fused with a tripartite activator, VP64-p65-Rta (VPR) 
[43]. However, although the latter approach could produce more copies of the full-length 
NF1, it will also face acute limitations in the cloning capacity and transduction efficiency of 
AAV vectors.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Overexpression of GRD suppressed MPNST cells
A. NF1 expression in MPNST cells. Western blotting was performed with the lysates of 
NF1-related MPNST cells (NF90–8, sNF96.2 and ST88–14), NF1-unrelated MPNST 
STS26T, and human Schwann cells (HSC).
B. Overexpression of NF1-GRD reduced Ras activities in MPNST cells. ST88–14 and 
NF90–8 were transduced by EGFP or GRD-2HA lentivirus and cell lysates were subjected 
to pulldown assay with GST-Raf-RBD. Western blotting was performed with indicated 
antibodies. GTPγS and GDP represent the positive or negative control, respectively.
C. NF1-GRD suppressed the growth of MPNST cells. MPNST cells were transduced with 
EGFP or GRD-2HA via lentivirus in 96 well plates and viable cells were measured after 72 
hrs. Three biological samples were measured in each date point and P values were evaluated 
by two-tailed t-test.
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Figure 2. Transduction of EGFP with various AAVs in ST88–14 and NF90–8 cells
A. Transduction efficacies of different AAV vectors in ST88–14 cells. ST88–14 cells plated 
in 96 well plates were transduced with indicated AAVs at MOI 1000 or 5000. Green 
fluorescent signals were measured after 5 days. Three biological samples were measured in 
each data point and statistical significance was evaluated by two-tailed t-test.
B. Fluorescence images of EGFP in ST88–14 cells transduced by selected AAVs. Nuclei 
were stained by NucBlue Live Cell Stain in blue.
C. Transduction efficacies of different AAV vectors in NF90–8 cells. NF90–8 cells plated in 
96 well plates were transduced with indicated AAVs at MOI 1000 or 5000. Green 
fluorescent signals were measured after 5 days.
D. Fluorescence images of EGFP in NF90–8 cells transduced by selected AAVs. Nuclei 
were stained by NucBlue Live Cell Stain in blue.
Bai et al. Page 13
Gene Ther. Author manuscript; available in PMC 2019 November 24.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 3. Transduction of EGFP with various AAVs in sNF96.2 and HSC cells
A. Transduction efficacies of different AAV vectors in sNF96.2 cells. sNF96.2 cells plated in 
96 well plates were transduced with indicated AAVs at MOI 1000 or 5000. Green 
fluorescent signals were measured after 5 days. Three biological samples were measured in 
each data point and statistical significance was evaluated by two-tailed t-test.
B. Fluorescence images of EGFP in sNF96.2 cells transduced by selected AAVs. Nuclei 
were stained by NucBlue Live Cell Stain in blue.
C. Green fluorescence staining of human spinal nerve Schwann cells with anti-S100 
antibody.
D. Transduction efficacies of different AAV vectors in human Schwann cells. HSC plated in 
96 well plates were transduced with indicated AAVs at MOI 1000 or 5000. Green 
fluorescent signals were measured after 5 days.
E. Fluorescence images of EGFP in HSC transduced by selected AAVs. Nuclei were stained 
by NucBlue Live Cell Stain in blue.
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Figure 4. Suppression of MPNST cells by GRD and GRD-C10 transduced by AAV-DJ
A. Transduction of GRD-2HA and 2HA-GRD-C10 in NF90–8 cells by AAV-DJ. NF90–8 
cells were transduced at MOI 5000 by AAV-DJ carrying EGFP (control), GRD-2HA or 
2HA-GRD-C10. Anti-HA western blot showed the expression of GRD-2HA and 2HA-
GRD-C10, and anti-pERK1/2 blot demonstrated the complete inhibition of ERK1/2 (p42/44) 
phosphorylation by GRD-C10 construct. Anti-ErK1/2 blot showed the total levels of Erk1/2 
in the lysates, whereas anti-βActin was used as control of housekeeping gene.
B. Anti-HA immunofluorescence images of NF90–8 cells transduced with GRD-2HA or 
2HA-GRD-C10 by AAV-DJ. Nuclei were stained by DAPI in blue.
C-E. Inhibition of MPNST cells by GRD and GRD-C10 transduced by AAV-DJ. NF90–8, 
ST88–14and sNF96.2 cells were plated in 96 well plates and incubated with AAV-DJ 
carrying EGFP, GRD-2HA or 2HA-GRD-C10 constructs at MOI 5000. After 4 days, viable 
cells were measured. Three biological samples were measured in each data point and P 
values were evaluated by two-tailed t-test.
F and G. NF90–8 and ST8814 cells were transduced by control AAV-DJ or AAV-DJ-2HA-
GRD-C10 at MOI 5000. After 2 days, cells were harvested, stained by propidium iodide and 
analyzed by flow cytometry (n=3). Fractions were calculated and P values were evaluated by 
two-tailed t-test.
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Figure 5. STS26 and human Schwann cells were not significantly affected by GRD and GRD-
C10 transduced by AAV-DJ.
A. Transduction efficacies of different AAV vectors in STS26T cells. Cells plated in 96 well 
plates were transduced with indicated AAVs at MOI 5000. Green fluorescent signals were 
measured after 5 days. Three biological samples were measured in each data point and 
statistical significance was evaluated by two-tailed t-test.
B. Fluorescence images of EGFP in STS26T cells transduced by indicated AAVs. Nuclei 
were stained by NucBlue Live Cell Stain in blue.
C and D, STS26T MPNST cells and human Schwann cells were plated in 96 well plates and 
incubated with AAV-DJ carrying EGFP, GRD-2HA or 2HA-GRD-C10 constructs at MOI 
5000. After 4 days, viable cells were measured. Three biological samples were measured in 
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each data point and statistical significance was evaluated by two-tailed t-test. NS: not 
significant, p > 0.05.
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